Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Gefapixant

Catalog No.: 187122
Cas No.: 1015787-98-0
Purity : >98%

Gefapixant是一种嘌呤能受体拮抗剂。

For research use only. We do not sell to patients.

Chemical Information

名称Gefapixant
Iupac 化学名称5-[(2,4-diaminopyrimidin-5-yl)oxy]-2-methoxy-4-(propan-2-yl)benzene-1-sulfonamide
同义词Gefapixant; MK-7264; MK 7264; MK7264; AF-219; AF219; AF 219; RO4926219; RO-4926219; RO 4926219;
英文同义词Gefapixant; MK-7264; MK 7264; MK7264; AF-219; AF219; AF 219; RO4926219; RO-4926219; RO 4926219;
分子式C14H19N5O4S
分子量353.39
SmileO=S(C1=CC(OC2=CN=C(N)N=C2N)=C(C(C)C)C=C1OC)(N)=O
InChiKeyHLWURFKMDLAKOD-UHFFFAOYSA-N
InChiInChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
Cas号1015787-98-0
Related CAS

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
BulkEnquiryEnquiryEnquiry
Request Bulk Quote Download MSDS 电话 : +86-27-65522453   Email : sales@sun-shinechem.com
Formulation 类白色至白色固体
纯度>98%
存储短期可在0-4度保存,数天至数月;长期可在-20度保存三年。
可溶性可溶于DMSO
Handling
运输条件可在常温下运输
HS Code
Coming soon.
Targets
Mechanism
Cell study
Animal study
Clinical study

1: Wang J, Wang Y, Cui WW, Huang Y, Yang Y, Liu Y, Zhao WS, Cheng XY, Sun WS, Cao P, Zhu MX, Wang R, Hattori M, Yu Y. Druggable negative allosteric site of P2X3 receptors. Proc Natl Acad Sci U S A. 2018 May 8;115(19):4939-4944. doi: 10.1073/pnas.1800907115. Epub 2018 Apr 19. PubMed PMID: 29674445; PubMed Central PMCID: PMC5948998.

2: Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol. 2018 May;151:157-165. doi: 10.1016/j.bcp.2017.07.016. Epub 2017 Jul 21. Review. PubMed PMID: 28735873.

3: Sheridan C. Merck stakes out 'irritable' neuron territory with $1.25 billion. Nat Biotechnol. 2016 Sep 8;34(9):900. doi: 10.1038/nbt0916-900. PubMed PMID: 27606448.

4: Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015 Mar 28;385(9974):1198-205. doi: 10.1016/S0140-6736(14)61255-1. Epub 2014 Nov 25. PubMed PMID: 25467586.

5: Morice AH. Developing antitussives the clinician's pipeline-what do we need? J Thorac Dis. 2014 Oct;6(Suppl 7):S735-8. doi: 10.3978/j.issn.2072-1439.2014.08.40. Review. PubMed PMID: 25383208; PubMed Central PMCID: PMC4222922.

6: Ochoa-Cortes F, Liñán-Rico A, Jacobson KA, Christofi FL. Potential for developing purinergic drugs for gastrointestinal diseases. Inflamm Bowel Dis. 2014 Jul;20(7):1259-87. doi: 10.1097/MIB.0000000000000047. Review. PubMed PMID: 24859298; PubMed Central PMCID: PMC4340257.

7: Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013 Dec 19;7:267. doi: 10.3389/fncel.2013.00267. Review. PubMed PMID: 24391544; PubMed Central PMCID: PMC3867694.


Chemical Structure

187122 - Gefapixant | CAS 1015787-98-0

Quick inquiry

Change